HL22
HL22 is a harmaline derivative. HL22 significantly inhibits HCT116, MGC803 and MCF7 cancer cell lines, and inhibits MGC803 cell migration and monoclonal formation. The anti-cancer mechanism of HL22 is related to a variety of metabolic pathways and can be used in the study of cancer[1].
Product Specifications
UNSPSC
12352005
Target
Drug Derivative
Related Pathways
Others
Field of Research
Cancer
Smiles
COC1=CC=C2C(N(CCCCCN3C4=CC(OC)=CC=C4C5=C3C(C)=NCC5)C6=C2C=CN=C6C)=C1
Molecular Formula
C31H34N4O2
Molecular Weight
494.63
References & Citations
[1]Liu Y, et al. Synthesis of harmaline N-9 derivatives and investigation of in vitro anticancer activity. Bioorg Med Chem Lett. 2025 Jan 13;119:130106.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
031778-ML650 100 µL
ALDH6A1, CT (ALDH6A1, MMSDH, Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial, Aldehyde dehydrogenase family 6 member A1) (MaxLight 650) discontinued
Sign In for Pricing
View Details